3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Breast Neoplasms
30
Neoplasm Metastasis
10
Carcinoma, Non-Small-Cell Lung
8
Stomach Neoplasms
7
Neoplasms
6
Colorectal Neoplasms
6
Adenocarcinoma
6
Pancreatic Neoplasms
3
Ovarian Neoplasms
3
Endometrial Neoplasms
3
Advanced Solid Tumor
3
Triple Negative Breast Neoplasms
2
Sarcoma
2
Prostatic Neoplasms
2
Melanoma
2
HER2-positive Gastric Cancer
2
Gastrointestinal Neoplasms
2
Esophageal Neoplasms
2
Carcinoma, Renal Cell
2
Brain Neoplasms
2
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Urethral Neoplasms
1
Unresectable Locally Recurrent Breast Cancer
1
Thyroid Neoplasms
1
Testicular Neoplasms
1
Solid Cancer
1
Interventions
Paclitaxel
32
Carboplatin
23
liposomal doxorubicin
14
pembrolizumab
12
Topotecan
10
Bevacizumab
10
Gemcitabine
9
mirvetuximab soravtansine
8
olaparib
6
Cisplatin
6
1-dodecylpyridoxal
6
rucaparib
5
Nivolumab
5
Cyclophosphamide
5
oregovomab
4
farletuzumab
3
catumaxomab
3
Standard of Care
3
Irinotecan
3
Fulvestrant
3
CCV-AV protocol
3
talazoparib
2
sacituzumab govitecan
2
ribociclib
2
phenoxodiol
2
pegfilgrastim
2
pazopanib
2
palbociclib
2
niraparib
2
fludarabine
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Carcinoma, Ovarian Epithelial
×
trastuzumab deruxtecan
×
Clear all
NCT06819007
2026-05-26
DO-01
Daiichi Sankyo
Phase 3
Recruiting
582 enrolled